摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one | 1160948-06-0

中文名称
——
中文别名
——
英文名称
(1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one
英文别名
(1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.110,13.01,10.02,7]nonadeca-2(7),3,5-trien-14-one
(1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one化学式
CAS
1160948-06-0
化学式
C21H25NO3
mdl
——
分子量
339.434
InChiKey
DFCRDTHYBCKRGA-XRXFAXGQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    25
  • 可旋转键数:
    2
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    (1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one氢气 、 palladium(II) hydroxide 、 potassium carbonate溶剂黄146N,N-二异丙基乙胺lithium chloride 作用下, 以 四氢呋喃甲醇乙醚N,N-二甲基甲酰胺 为溶剂, 反应 86.75h, 生成 (6R,6aS,10R,11aR)-14-(cyclopropylmethyl)-10-(2-hydroxy-2-methyl-3-phenylpropyl)-6,7,8,9,10,11-hexahydro-5H-6,11a-(epiminoethano)-6a,10-epoxycyclohepta-[a]naphthalen-2-ol
    参考文献:
    名称:
    以C-高吗啡喃衍生物为先导化合物,可获得更安全和更临床有用的镇痛药。
    摘要:
    丁丙诺啡对中度至重度疼痛具有强镇痛作用。尽管丁丙诺啡可以比其他阿片类镇痛药更安全地使用,但在临床上仍有改善的空间。与丁丙诺啡相比,研究与丁丙诺啡结构相关的化合物应该是一种获得新型镇痛药的方法,该镇痛药与丁丙诺啡相比具有更安全,更完善的特性。在我们先前的研究过程中,我们观察到通过环化C-高吗啡喃获得的衍生物在结构上与丁丙诺啡有关。因此,我们合成了在侧链上具有各种氧官能度的环化C-高吗啡喃衍生物,并评估了它们在体外对阿片受体的药理作用。在测试的化合物中,具有N-甲基基团的甲基酮2a对μ和δ受体显示完全激动作用,对κ受体显示部分激动作用。这些性质与丁丙诺啡的主要代谢产物去甲丁丙诺啡相似,据报道有助于丁丙诺啡的抗伤害感受作用。从这些结果,我们得出结论,环化的C-高吗啡喃可能是获得具有丁丙诺啡样性质的新型镇痛药的潜在先导化合物。
    DOI:
    10.1248/cpb.c17-00385
  • 作为产物:
    描述:
    (7R,10R,14R,15S)-18-(cyclopropylmethyl)-7,15-epoxy-3-methoxy-C-homomorphinan-6-one三溴化硼 作用下, 以 二氯甲烷 为溶剂, 以87%的产率得到(1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one
    参考文献:
    名称:
    使用新的重排反应合成具有氧杂双环[3.2.1]辛烷骨架的新型阿片样物质配体
    摘要:
    制备具有1,3,5-三氧杂氮杂三喹烷骨架的三聚体的尝试导致发现了新的重排反应,该反应提供了具有氧杂环[3.2.1]辛烷骨架的化合物,提出了其反应机理。基于这种机理,我们以优异的收率从二甲基乙缩醛中间体合成了重排产物。具有氧杂双环[3.2.1]辛烷骨架的化合物显示出对μ和κ的高亲和力,但对δ阿片受体类型没有亲和力。该化合物有望成为新型κ选择性配体的关键中间体。
    DOI:
    10.1016/j.bmcl.2009.03.068
点击查看最新优质反应信息

同类化合物

普罗啡烷 (9R,10R)-15-(环丙基甲基)-10-甲基-11-氧杂-17-氮杂四环[7.5.3.01,10.0(2,7)]十七-2,4,6-三烯-4-醇 3-methoxy-14β-hydroxy-6-oxamorphinan (1S,3aR,5aS,6R,11bR,11cS)-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(iminoethano)-1,5a-epoxynaphtho[1,2-e]indole (+)-14β-Hydroxy-3-methoxy-17-methyl-6-oxamorphinan N-Propargyl-3-methoxy-14β-methyl-8-oxamorphinan N-Propargyl-3-hydroxy-14β-methyl-8-oxamorphinan NS 28 17-cyclopropylmethyl-7,14α-epoxy-7,14-seco-8-nor-morphinan-3-ol 17-cyclopropylmethyl-7,14α-epoxy-3-methoxy-7,14-seco-8-nor-morphinane (4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-hydroxy-11-phenyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one NS22 (1S,5R,13R,14R,17S)-4-methyl-12,19-dioxa-4-azahexacyclo[9.6.1.114,17.01,13.05,17.07,18]nonadeca-7(18),8,10-trien-10-ol KNT-63 (1R,9R,10S,13R)-18-(cyclopropylmethyl)-4-hydroxy-19-oxa-18-azapentacyclo[7.6.3.1^{10,13}.0^{1,10}.0^{2,7}]nonadeca-2(7),3,5-trien-14-one (1S,9R,10R)-17-(cyclopropylmethyl)-11-hydroxy-4-methoxy-12-oxa-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one 17-cyclopropylmethyl-6α,14-epoxy-4,5α-epoxy-3-benzyloxymorphinan Proxorphan tartrate (1S,3aS,5aS,6R,11bR,11cR)-3-benzyl-14-(cyclopropylmethyl)-3a,11-dihydroxy-10-methoxy-1,3,3a,4,5,6,7,11c-octahydro-2H-6,11b-(iminoethano)-1,5a-epoxynaphtho[1,2-e]indol-2-one (4bR,8R,8aS,9aS,11aS,11bR)-7-allyl-11-benzyl-1-hydroxy-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one (4bR,8R,8aS,9aS,11aS,11bR)-11-benzyl-7-methyl-1-hydroxy-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one (4bR,8R,8aS,9aS,11aS,11bR)-11-benzyl-1-hydroxy-7-(2-phenethyl)-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one (4bR,8R,8aS,9aS,11aS,11bR)-11-benzyl-1-hydroxy-7-isobutyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one (4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-hydroxy-11-(2-phenethyl)-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one (1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-10-methoxy-12,19-dioxa-4-azahexacyclo[9.6.1.114,17.01,13.05,17.07,18]nonadeca-7(18),8,10-triene (4bR,8R,8aS,9aS,11aS,11bR)-11-benzyl-7-(cyclopropylmethyl)-1-hydroxy-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one 3-methoxy-10α,17-dimethyl-6-oxamorphinan 3-methoxy-17-methyl-10-methylene-6-oxamorphinan rac-7,14α-epoxy-3-methoxy-7,14-seco-8-nor-morphinane (1R,9S,10S)-17-(cyclopropylmethyl)-13-oxa-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol (1S,9R,10R)-10,17-dimethyl-11-oxa-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol (1S,9R,10S)-17-(cyclopropylmethyl)-10-methyl-11-oxa-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol 16-(Cyclopropylmethyl)-10,12-dimethyl-11-oxa-16-azatetracyclo[7.4.3.01,10.02,7]hexadeca-2(7),3,5-trien-4-ol 3-Hydroxy-17-methyl-8-oxamorphinan 12,16-Dimethyl-11-oxa-16-azatetracyclo[7.4.3.01,10.02,7]hexadeca-2(7),3,5-trien-4-ol rac-(6Ξ)-6,14β-epoxy-17-methyl-7,14-seco-8-nor-morphinane (1R,9R,10S)-16-cyclobutyl-10,12-dimethyl-11-oxa-16-azatetracyclo[7.4.3.01,10.02,7]hexadeca-2(7),3,5-trien-4-ol 1-[(1R,9R,10S)-10,16-dimethyl-11-oxa-16-azatetracyclo[7.4.3.01,10.02,7]hexadeca-2,4,6-trien-12-yl]-N,N-dimethylmethanamine;hydrochloride (8S)-6-benzyl-21-(cyclopropylmethyl)-15-hydroxy-11,13,25-trioxa-6,21-diazahexacyclo[12.9.1.12,8.01,9.02,20.018,24]pentacosa-14,16,18(24)-trien-7-one (3S)-5,20-bis(cyclopropylmethyl)-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-15-ol (3S)-5-benzyl-20-(cyclopropylmethyl)-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-16-ol [(3R,6S)-14-hydroxy-19-(2-hydroxy-2-methylpropyl)-7-oxa-4,19-diazahexacyclo[7.7.3.13,8.01,8.02,6.011,16]icosa-11(16),12,14-trien-4-yl]-phenylmethanone [(3S)-20-(cyclopropylmethyl)-5-(4,6-dimethyl-1,2-dihydropyrimidin-2-yl)-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-15-yl] trifluoromethanesulfonate 3-[(3S)-20-(cyclopropylmethyl)-15-methoxy-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-triene-5-carbonyl]benzonitrile [(3S)-20-(cyclopropylmethyl)-15-hydroxy-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-5-yl]-(2-fluorophenyl)methanone (1R,3S,9S,10R)-20-(cyclopropylmethyl)-5-(4,6-dimethylpyrimidin-2-yl)-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-15-ol (1S,3aR,5aS,6R,11bR,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(iminoethano)-1,5a-epoxynaphtho[1,2-e]indol-11-ol (1S,3aR,5aS,6R,11bR,11cS,12S)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-1,2,3a,4,5,6,7,11c-octahydro-1H-6,11b-(iminoethano)-1,5a-epoxynaphtho[1,2-e]indol-12-ol (1R,2S,3S,6R,9S,10R)-20-(cyclopropylmethyl)-5-(2-phenylethyl)-21-oxa-5,20-diazahexacyclo[8.7.3.13,9.01,9.02,6.012,17]henicosa-12(17),13,15-trien-15-ol (1S,3aR,5aS,6R,11bR,11cS,12S)-3-benzyl-14-(cyclopropylmethyl)-1,2,3a,4,5,6,7,11c-octahydro-1H-6,11b-(immoethano)-1,5a-epoxynaphtho[1,2-e]indole-10,12-diol